Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort

被引:8
作者
Lions, C. [1 ]
Cabras, O. [2 ]
Cotte, L. [3 ]
Huleux, T. [4 ]
Gagneux-Brugnon, A. [5 ]
Makinson, A. [6 ,7 ]
Cabie, A. [8 ,9 ]
Bonnet, B. [10 ]
Duvivier, C. [11 ,12 ,13 ,14 ,25 ]
Hocqueloux, L. [15 ]
Cua, E. [16 ]
Cheret, A. [17 ,23 ]
Hustache-Mathieu, L. [18 ]
Obry-Roguet, V. [1 ]
Jacomet, C. [19 ]
Poizot-Martin, I. [1 ,20 ,21 ]
Drobacheff-Thiebaut, C.
Foltzer, A.
Bouiller, K.
Chirouze, C.
Lepiller, Q.
Bozon, F.
Babre, O.
Muret, P.
Laurichesse, H.
Lesens, O.
Vidal, M.
Mrozek, N.
Aumeran, C.
Baud, O.
Corbin, V.
Letertre, P.
Casanova, S.
Prouteau, J.
Hoen, B.
Lamaury, I.
Fabre, I.
Curlier, E.
Ouissa, R.
Schepers, K.
Herrmann-Storck, C.
Dournon, N.
Merrien, D.
Perre, P.
Guimard, T.
Bollangier, O.
Leautez, S.
Morrier, M.
Ader, F.
Biron, F.
机构
[1] Aix Marseille Univ, Hop St Marguerite, APHM, Serv Immunohematol Clin, Marseille, France
[2] CHU Bichat, Serv Malad Infect & Trop, Paris, France
[3] Hosp Civils Lyon, Serv Malad Infect & Trop, Lyon, France
[4] CH Tourcoing, Serv Univ Malad Infect & Voyageur, Tourcoing, France
[5] Univ Lyon, Serv Infectiol, CHU St Etienne, Grp Immunite Muqueuses & Agents Pathogenes,Inst P, Lyon, France
[6] Univ Hosp Montpellier, Infect & Trop Dis Dept, Montpellier, France
[7] Univ Montpellier, INSERM, UMI 233, U1175,IRD, Montpellier, France
[8] CHU Martinique, Serv Malad Infect & Trop, INSERM, CIC 1425, Fort De France, Martinique, France
[9] Univ Antilles, EA 4537, Basse Terre, Guadeloupe, France
[10] CHU HOTEL DIEU, Malad Infect & trop, Nantes, France
[11] Hop Necker Enfants Malad, APHP, Serv Malad Infect & Trop, Ctr Infectiol Necker Pasteur, F-75015 Paris, France
[12] Inst Pasteur, Ctr Med, Ctr Infectiol Necker Pasteur, F-75015 Paris, France
[13] Univ Paris 05, Sorbonne Paris Cite, Equipe Accueil, EA 7327, F-75015 Paris, France
[14] IHU Imagine, F-75015 Paris, France
[15] CHR Orleans La Source, Serv Malad Infect & Trop, Orleans, France
[16] CHU Nice, Serv Malad Infect & Trop, Nice, France
[17] CHU Kremlin Bicetre, AP HP, Serv Med Interne, Le Kremlin Bicetre, France
[18] CHU Besancon, Serv Malad Infect & Trop, Besancon, France
[19] CHU Clermont Ferrand, Serv Malad Infect & Trop, Clermont Ferrand, France
[20] Aix Marseille Univ, INSERM, IRD, SESSTIM,APHM St Marguerite,Clin Immunohematol Uni, Marseille, France
[21] Ctr Informat & Soins Immunodeficience Humaine & H, Immuno Hematol Unit, Serv Immunohematol Clin, 270 Blvd St Marguerite, F-13009 Marseille, France
[22] IHU, Marseille, France
[23] Bicetre, Paris, France
[24] Bichat, Paris, France
[25] Necker Pasteur, Paris, France
[26] La Pitie, Paris, France
关键词
Pre-exposure prophylaxis; PrEP; HIV; Missed opportunities; HIV testing; SEXUALLY-TRANSMITTED INFECTIONS; MEN; SEX; PEOPLE; PREP;
D O I
10.1186/s12879-019-3915-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundHIV pre-exposure prophylaxis (PrEP) was implemented in France in November 2015 based on individual-level risk factors for HIV infection. We evaluated the proportion of missed opportunities for PrEP among newly HIV-diagnosed people entering the Dat'AIDS cohort in 2016.MethodsMulticenter retrospective analysis in 15 French HIV clinical centers of patients with a new diagnosis of HIV infection. Among them we differentiated patients according to the estimated date of infection: those occurring in the PrEP area (a previous negative HIV test in the last 12months or those with an incomplete HIV-1 western blot (WB) with no HIV-1 anti-Pol-antibody at time of HIV diagnosis) and those in the pre-PrEP area (older infections). Epidemiological, biological and clinical data at HIV diagnosis were collected. Clinicians retrospectively identified potential eligibility for PrEP based on individual-level risk factors for HIV infection among those infected in the PrEP area.ResultsAmong 966 patients with a new HIV diagnosis, 225 (23.3%) were infected in the PrEP area and 121 (53.8%) had complete data allowing evaluation of PrEP eligibility. Among them, 110 (91%) would have been eligible for PrEP, median age 31years, with 68 (75.6%) born in France and 10 (11.1%) in Central/West Africa, with more than one previous STI in 19 (15.7%). The main eligibility criteria for PrEP were being a man who had sex with men or transgender 91 (82.7%) with at least one of the following criteria: unprotected anal sex with 2 partners in the last 6months: 67 (60.9%); bacterial sexually transmitted infection in the last 12months: 33 (30%); Use of psychoactive substances in a sexual context (chemsex): 16 (14.5%). PrEP was indicated for other HIV risk factors in 25 (22.7%).ConclusionWith 91% (110/121) of patients infected in the PrEP area eligible for PrEP, this study highlights the high potential of PrEP in avoiding new infection in France but also shows a persistent delay in HIV testing. Thus, an important limit on PrEP implementation in France could be insufficient screening and care access.
引用
收藏
页数:9
相关论文
共 50 条
[31]   A Review of HIV Pre-exposure Prophylaxis Streamlining Strategies [J].
Siegler, Aaron J. ;
Steehler, Kevin ;
Sales, Jessica M. ;
Krakower, Douglas S. .
CURRENT HIV/AIDS REPORTS, 2020, 17 (06) :643-653
[32]   Dynamics and optimal control of a spatial diffusion HIV/AIDS model with antiretrovial therapy and pre-exposure prophylaxis treatments [J].
Wang, Liping ;
Din, Anwarud ;
Wu, Peng .
MATHEMATICAL METHODS IN THE APPLIED SCIENCES, 2022, 45 (16) :10136-10161
[33]   Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis [J].
Ibrahim, Mustafa E. ;
Castillo-Mancilla, Jose R. ;
Yager, Jenna ;
Brooks, Kristina M. ;
Bushman, Lane ;
Saba, Laura ;
Kiser, Jennifer J. ;
MaWhinney, Samantha ;
Anderson, Peter L. .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2021, 37 (06) :421-428
[34]   HIV Prevention After Discontinuing Pre-Exposure Prophylaxis: Conclusions From a Case Study [J].
Jonas, Kai J. ;
Yaemim, Natthakhet .
FRONTIERS IN PUBLIC HEALTH, 2018, 6
[35]   Pre-exposure of Prophylaxis to Prevent HIV Infection - current Data and Recommendations [J].
Kuemmerle, T. ;
Foewtkenheuer, G. .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (44) :2285-2288
[36]   The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities [J].
Haberer, Jessica E. ;
Mujugira, Andrew ;
Mayer, Kenneth H. .
LANCET HIV, 2023, 10 (06) :E404-E411
[37]   HIV pre-exposure prophylaxis Knowledge and attitudes among general practitioners [J].
Lane, William ;
Heal, Clare ;
Banks, Jennifer .
AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2019, 48 (10) :722-727
[38]   Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic [J].
Killelea, Amy ;
Johnson, Jeremiah ;
Dangerfield, Derek T. ;
Beyrer, Chris ;
McGough, Matthew ;
McIntyre, John ;
Gee, Rebekah E. ;
Ballreich, Jeromie ;
Conti, Rena ;
Horn, Tim ;
Pickett, Jim ;
Sharfstein, Joshua M. .
JOURNAL OF LAW MEDICINE & ETHICS, 2022, 50 :8-23
[39]   Online Prescriptions to HIV Pre-Exposure Prophylaxis and Pre-Exposure Prophylaxis Uptake [J].
Wille, Lexie ;
Parent, Mike C. .
AIDS PATIENT CARE AND STDS, 2020, 34 (12) :499-501
[40]   Nurse's role in pharmacological pre-exposure prophylaxis of HIV infection [J].
Bartkowiak, Grzegorz ;
Kryczka, Tomasz .
PIELEGNIARSTWO XXI WIEKU-NURSING IN THE 21 CENTURY, 2022, 21 (04) :235-243